SynthesisSystematic reviews2024
Predictors of mortality in severe pneumonia patients: a systematic review and meta-analysis.
Synthesis in Systematic reviews, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk prediction models for mortality in patients with severe pneumonia: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Optimized Individualized Nursing Improves Recovery and Reduces Complications in ICU Patients with Severe Pneumonia.Organogenesis · 2025Trial
- Performance and Validation of a New Long-Term Mortality Risk Score in Community-Acquired Pneumonia: A Colombian Cohort.Infectious disease reports · 2026Article
- Review
- Cumulative respiratory pathogen detection burden by multiplex PCR is associated with mortality in a TB-enriched ICU cohort.Microbiology spectrum · 2026Article
- Associations between pneumonia with sepsis, sepsis-associated encephalopathy, and mortality in adult intensive care unit: a retrospective analysis using MIMIC-IV database.Journal of thoracic disease · 2026Article
- ROS-responsive nanogels enable inhaled CD24 immunotherapy for selective hyperinflammation suppression in severe pneumonia.Science advances · 2026Article
- Pneumonia Etiology and Risk Factors in a Tertiary Hospital During the COVID-19 Era: A Retrospective Analysis (2020-2024).Journal of general internal medicine · 2026Article
- Antimicrobial Resistance and Clinical Outcome Among Hospitalized Bacterial Pneumonia: A Retrospective Cohort Study in Indonesian Tertiary Hospital.Antibiotics (Basel, Switzerland) · 2026Article
- Clinical characteristics and risk factors associated with mortality in patients with severe community-acquired pneumonia in the intensive care unit.Journal of thoracic disease · 2026Article
- Systemic corticosteroids for severe community-acquired pneumonia: a narrative review of mechanisms and critical appraisal of recent trials in ICU.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Oropharyngeal Microbiota Associated with Sore Throat in Acute Upper Respiratory Tract Infections.Current microbiology · 2026Article
- Association of the LncRNA TINCR rs2288947 polymorphism with survival outcomes in severe pneumonia among Han Chinese children.European journal of medical research · 2026Article
- Interleukin-40 as a biomarker of mortality risk in patients with severe pneumonia.Frontiers in immunology · 2026Article
- Standardized Prospective Intervention in Hospitalized Patients with Bacterial Pneumonia.Journal of clinical medicine · 2025Article
- Systemic Inflammatory Indices (SII and SIRI) in 30-Day Mortality Risk Stratification for Community-Acquired Pneumonia: A Study Alongside CURB-65 and PSI.Pathogens (Basel, Switzerland) · 2025Article
- Development and multi-database validation of interpretable machine learning models for predicting In-Hospital mortality in pneumonia patients: A comprehensive analysis across four healthcare systems.Respiratory research · 2025Article
- Sex differences in sepsis outcomes across the lifespan: a population-based cohort study in Germany.Critical care (London, England) · 2025Article
- A Cohort Study of Pediatric Severe Community-Acquired Pneumonia Involving AI-Based CT Image Parameters and Electronic Health Record Data.Infectious diseases and therapy · 2025Article
- Assessment of Mortality Risk in Patients With Community-Acquired Pneumonia: Role of Novel Inflammatory Biomarkers.Journal of clinical laboratory analysis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSevere pneumonia has consistently been associated with high mortality. We sought to identify risk factors for the mortality of severe pneumonia to assist in reducing mortality for medical treatment.
methodsElectronic databases including PubMed, Web of Science, EMBASE, Cochrane Library, and Scopus were systematically searched till June 1, 2023. All human research were incorporated into the analysis, regardless of language, publication date, or geographical location. To pool the estimate, a mixed-effect model was used. The Newcastle-Ottawa Scale (NOS) was employed for assessing the quality of included studies that were included in the analysis.
resultsIn total, 22 studies with a total of 3655 severe pneumonia patients and 1107 cases (30.29%) of death were included in the current meta-analysis. Significant associations were found between age [5.76 years, 95% confidence interval [CI] (3.43, 8.09), P < 0.00001], male gender [odds ratio (OR) = 1.47, 95% CI (1.07, 2.02), P = 0.02], and risk of death from severe pneumonia. The comorbidity of neoplasm [OR = 3.37, 95% CI (1.07, 10.57), P = 0.04], besides the presence of complications such as diastolic hypotension [OR = 2.60, 95% CI (1.45, 4.67), P = 0.001], ALI/ARDS [OR = 3.63, 95% CI (1.78, 7.39), P = 0.0004], septic shock [OR = 9.43, 95% CI (4.39, 20.28), P < 0.00001], MOF [OR = 4.34, 95% CI (2.36, 7.95), P < 0.00001], acute kidney injury [OR = 2.45, 95% CI (1.14, 5.26), P = 0.02], and metabolic acidosis [OR = 5.88, 95% CI (1.51, 22.88), P = 0.01] were associated with significantly higher risk of death among patients with severe pneumonia. Those who died, compared with those who survived, differed on multiple biomarkers on admission including serum creatinine [Scr: + 67.77 mmol/L, 95% CI (47.21, 88.34), P < 0.00001], blood urea nitrogen [BUN: + 6.26 mmol/L, 95% CI (1.49, 11.03), P = 0.01], C-reactive protein [CRP: + 33.09 mg/L, 95% CI (3.01, 63.18), P = 0.03], leukopenia [OR = 2.63, 95% CI (1.34, 5.18), P = 0.005], sodium < 136 mEq/L [OR = 2.63, 95% CI (1.34, 5.18), P = 0.005], albumin [- 5.17 g/L, 95% CI (- 7.09, - 3.25), P < 0.00001], PaO
conclusionsOlder age and male gender might face a greater risk of death in severe pneumonia individuals. The mortality of severe pneumonia may also be significantly impacted by complications such diastolic hypotension, ALI/ARDS, septic shock, MOF, acute kidney injury, and metabolic acidosis, as well as the comorbidity of neoplasm, and laboratory indicators involving Scr, BUN, CRP, leukopenia, sodium, albumin, PaO SYSTEMATIC REVIEW REGISTRATION: PROSPERO Protocol Number: CRD 42023430684.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.